Surgical Treatment for Morbid Obesity by Sleeve Gastrectomy Versus Gastric Bypass (SLEEVE)

Surgical Treatment for Morbid Obesity by Sleeve Gastrectomy Versus Gastric Bypass. Study Comparing Complications, Efficacy and Quality of Life.

The aim of this study is to assess that the sleeve gastrectomy can improve the risk benefit than the gastric bypass

Study Overview

Status

Completed

Conditions

Detailed Description

In the obese patient population, the frequency of patients presenting a severe morbid obesity (40 >= BMI <= 50), a super obesity (BMI >50), a super super obesity (BMI>60), and obese patients (BMI>35) with a failure of gastric banding is constantly increasing. In these patients, the surgery risk is proportionate to the weight and / or gastric surgery records.

This risk is high, in bariatric surgery, for gastric bypass procedure. This justifies the evaluation of new procedure to reduce the morbidity allowing the reduction of morbid /mortality associated with the intervention.

Study Type

Interventional

Enrollment (Actual)

280

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Saint-Denis, France, 93205
        • Service de chirurgie digestive / Centre Hospitalier Général de Saint-Denis Delafontaine

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patient aged from 18 to 60 years old
  • Patient having given his consent to the use of data from the project
  • Patient fulfilling the inclusion criteria for surgery of obesity according to the ANAES (french national health service)
  • Patient presenting one of the following criteria:

    • A morbid obesity strict with BMI> 40
    • A super obesity BMI> 50
    • A super super obesity BMI> 60
    • Obese patient in failure following the installation of a gastric banding with BMI> 35
    • obese patient 35>BMI>40 with a comorbidity
  • Preliminary agreement during the consultation of a psychiatrist / psychologist

Exclusion Criteria:

  • Patient with complications or co morbidities associated involving life to less 6 months
  • Patient presenting no anaesthetic indication
  • Patient presenting no psychiatric indication for obesity surgery
  • Patient not affiliated with a social security scheme
  • Pregnant Patient likely to breastfeed in the first year

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: 1
Sleeve gastrectomy
Laparoscopic sleeve gastrectomy is a restrictive procedure for the treatment for morbid obesity
Other Names:
  • SLEEVE
Active Comparator: 2
Gastric Bypass
Laparoscopic gastric bypass is a restrictive and difficult absorption procedure for the treatment of morbid obesity
Other Names:
  • BYPASS

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Composite criteria of morbid/mortality
Time Frame: during 18 months and 36 months
during 18 months and 36 months

Secondary Outcome Measures

Outcome Measure
Time Frame
Frequency of morbid events
Time Frame: during the follow up
during the follow up
Percentage of excess weight loss
Time Frame: during 18 and 36 months
during 18 and 36 months
Frequency of patients having a excess weight loss superior than 50%
Time Frame: during 36 months
during 36 months
Regression of morbidities
Time Frame: during 36 months
during 36 months
Rate serum ghrelin
Time Frame: at inclusion visit, 6, 12, 18 and 36 months
at inclusion visit, 6, 12, 18 and 36 months
Evaluation of quality of life and scores of precariousness, SF 36, EPWORTH Score, Lequesne' Score, Insecure' Score
Time Frame: at inclusion visit, 6, 12, 18 and 36 months
at inclusion visit, 6, 12, 18 and 36 months
Frequency of morbid/mortality events
Time Frame: during 36 months
during 36 months
Frequency of patients having excess weight loss superior than 50%
Time Frame: during 18 month
during 18 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Jean-Marc CATHELINE, MD, PhD, Assistance Publique - Hôpitaux de Paris / Hôpital De la Fontaine (St Denis)

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2008

Primary Completion (Actual)

April 1, 2015

Study Completion (Actual)

April 1, 2015

Study Registration Dates

First Submitted

July 25, 2008

First Submitted That Met QC Criteria

July 25, 2008

First Posted (Estimate)

July 28, 2008

Study Record Updates

Last Update Posted (Actual)

June 15, 2021

Last Update Submitted That Met QC Criteria

June 14, 2021

Last Verified

June 1, 2021

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity

Clinical Trials on Sleeve gastrectomy

3
Subscribe